John F. Flaherty

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study

Patrick Marcellin, Edward Gane, Nezam H. Afdhal et al. · The Lancet · 2012 · 1.8K citations

Medicine, Pharmacology, Pharmacotherapy +16

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

Edward Gane, Wai Kay Seto, Henry Lik‐Yuen Chan et al. · ˜The œLancet. Gastroenterology & hepatology · 2016 · 546 citations

Pharmacy, Infectious Diseases, Pharmacology +12

Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial

Henry Lik‐Yuen Chan, Scott Fung, Wai Kay Seto et al. · ˜The œLancet. Gastroenterology & hepatology · 2016 · 458 citations

Pharmacy, Infectious Diseases, Pharmacology +11

96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection

Kosh Agarwal, Maurizia Rossana Brunetto, Wai Kay Seto et al. · Journal of Hepatology · 2018 · 423 citations · Full text

Pharmacy, Infectious Diseases, Pharmacology +10

aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis

Rong Fan, George Papatheodoridis, Jian Sun et al. · Journal of Hepatology · 2020 · 349 citations · Full text

Medicine, Oncology, Cancer Epidemiology +16